Mostrar el registro sencillo del ítem
TFG-beta Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer
dc.contributor.author | Cárdenas Quesada, Nuria | |
dc.contributor.author | Márquez Lobo, Bélgica | |
dc.contributor.author | Núñez Torres, María Isabel | |
dc.date.accessioned | 2022-12-13T10:24:00Z | |
dc.date.available | 2022-12-13T10:24:00Z | |
dc.date.issued | 2022-11-09 | |
dc.identifier.citation | Cárdenas-Quesada, N... [et al.]. TFG-beta Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer. Int. J. Mol. Sci. 2022, 23, 13780. [https://doi.org/10.3390/ijms232213780] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/78418 | |
dc.description.abstract | Nowadays, the impact of the tumor-immune microenvironment (TME) in non-small-cell lung cancer (NSCLC) prognosis and treatment response remains unclear. Thus, we evaluated the expression of PD-L1, tumor-infiltrating lymphocytes (TILs), and transforming growth factor beta (TGF- ) in NSCLC to identify differences in TME, detect possible new prognostic factors, and assess their relationship. We retrospectively analyzed 55 samples from patients who underwent NSCLC surgery and had over a 5-year follow-up. PD-L1 expression was determined by immunohistochemistry following standard techniques. The presence of TILs was evaluated at low magnification and classified into two categories, “intense” and “non-intense”. Cytoplasmic TGF- staining visualization was divided into four categories, and unequivocal nuclear staining in >1% of viable tumor cells was defined as “present” or “absent”. Our aim was to identify differences in disease-free survival (DFS) and overall survival (OS). Tumor stage was the only objective prognostic factor for OS. PD-L1 expression and the presence of TILs had no prognostic impact, neither their combination. There seems to be a lower expression of PD-L1 and a higher expression of TILs in early stages of the disease. Our TGF- nuclear staining analysis was promising, since it was associated with worse DFS, revealing this protein as a possible prognostic biomarker of recurrence for resectable NSCLC. | es_ES |
dc.description.sponsorship | Andalusian Public Foundation for Biosanitary Research of Eastern Andalusia Alejandro Otero (FIBAO) | es_ES |
dc.description.sponsorship | Andalusian Health Service | es_ES |
dc.description.sponsorship | Andalusian public health system biobank S2000353 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | PD-L1 | es_ES |
dc.subject | TILs | es_ES |
dc.subject | TGF- beta | es_ES |
dc.subject | Prognostic factors | es_ES |
dc.subject | Checkpoint inhibition | es_ES |
dc.subject | Early-stage lung cancer | es_ES |
dc.title | TFG-beta Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.doi | 10.3390/ijms232213780 | |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |